Barclays PLC Increases Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID)

Barclays PLC raised its holdings in Ovid Therapeutics Inc. (NASDAQ:OVID) by 311.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 84,175 shares of the company’s stock after purchasing an additional 63,702 shares during the quarter. Barclays PLC’s holdings in Ovid Therapeutics were worth $98,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. DCF Advisers LLC lifted its position in shares of Ovid Therapeutics by 111.6% during the 2nd quarter. DCF Advisers LLC now owns 41,750 shares of the company’s stock valued at $32,000 after acquiring an additional 22,020 shares during the period. XTX Topco Ltd lifted its position in shares of Ovid Therapeutics by 46.2% during the 3rd quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock valued at $45,000 after acquiring an additional 12,076 shares during the period. FMR LLC lifted its position in shares of Ovid Therapeutics by 1,907.4% during the 3rd quarter. FMR LLC now owns 50,225 shares of the company’s stock valued at $59,000 after acquiring an additional 47,723 shares during the period. Verition Fund Management LLC acquired a new stake in shares of Ovid Therapeutics during the 3rd quarter valued at approximately $88,000. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Ovid Therapeutics during the 3rd quarter valued at approximately $102,000. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Trading Down 5.5 %

Shares of Ovid Therapeutics stock opened at $0.91 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.66 and a quick ratio of 5.66. Ovid Therapeutics Inc. has a 1 year low of $0.68 and a 1 year high of $4.10. The company has a market capitalization of $64.61 million, a P/E ratio of -1.94 and a beta of 0.34. The business has a 50 day moving average price of $1.08 and a 200 day moving average price of $1.06.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.15 million. Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. Sell-side analysts anticipate that Ovid Therapeutics Inc. will post -0.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Ovid Therapeutics in a research report on Wednesday, December 4th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $4.04.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.